Skandinaviska Enskilda Banken Ab (Publ) Iveric Bio, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$26.24 - $39.63 $19.6 Million - $29.5 Million	-745,542 Reduced 95.03%	39,000 $1.53 Million
Q1 2023 May 11, 2023	SELL	$18.67 - $24.56 $116,874 - $153,745	-6,260 Reduced 0.79%	784,542 $19.1 Million
Q4 2022 Feb 08, 2023	SELL	$17.24 - $23.95 $113,508 - $157,686	-6,584 Reduced 0.83%	790,802 $16.9 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $6.82 Million - $13.5 Million	725,155 Added 1003.94%	797,386 $14.3 Million
Q1 2022 May 11, 2022	BUY	$12.15 - $16.83 $877,606 - $1.22 Million	72,231 New	72,231 $1.22 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.